Retina/Vitreous News

The FDA granted 510(k) clearance for OCT angiography on the robotic Maestro2 OCT color fundus camera system, according to a press release from Topcon Healthcare.

Viridian Therapeutics reported positive topline data from the phase 3 THRIVE clinical trial of veligrotug for the treatment of active thyroid eye disease.

CARLSBAD, Calif. — In this Healio Video Perspective from the Women in Ophthalmology Summer Symposium, Lisa M. Nijm, MD, JD, discusses the burden of thyroid eye disease and how it affects quality of life.

The FDA cleared an investigational new drug application for OpCT-001, an investigational cell therapy for the treatment of primary photoreceptor diseases, according to a press release from BlueRock Therapeutics.

Less than 25% of patients with thyroid eye disease who underwent a full course of treatment with Tepezza required re-treatment, according to a study published in Ophthalmology.

Retinal ganglion cell layer thickness was significantly reduced in patients with severe COVID-19, which indicates an affinity for nerve cells, according to research published in the Open Journal of Ophthalmology.

Delayed diagnosis of congenital optic disc abnormalities increases the risk for complications and may affect visual prognosis, according to a study published in the Open Journal of Ophthalmology.

The retinal image-based, deep-learning cardiac BioAge model accurately stratified individuals by traditional cardiovascular disease risk biomarkers, with leukocyte telomere length inversely related to BioAge score, researchers reported.

Clearside Biomedical announced the completion of the final participant visit in its ODYSSEY phase 2b clinical trial of CLS-AX, an axitinib injectable suspension for neovascular age-related macular degeneration.

AiViva Biopharma announced that it has completed enrollment and dosing of the last patient in a phase 1 clinical trial of AIV007 for wet age-related macular degeneration and diabetic macular edema.